Keisuke Tamari1, Fumiaki Isohashi2, Yuichi Akino2, Osamu Suzuki2, Yuji Seo2, Yasuo Yoshioka2, Yoshito Hayashi3, Tsutomu Nishida3, Tetsuo Takehara3, Masaki Mori4, Yuichiro Doki4, Kazuhiko Ogawa2. 1. Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan tamari@radonc.med.osaka-u.ac.jp. 2. Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan. 3. Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan. 4. Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
Abstract
AIM: We investigated clinical and dosimetric factors influencing the risk of developing pericardial effusion (PCE) in patients with Stage I esophageal cancer undergoing definitive chemoradiotherapy. PATIENTS AND METHODS: Sixty-nine patients with Stage I esophageal cancer who underwent definitive chemoradiotherapy were retrospectively analyzed. Treatment comprised of three-dimensional conformal radiotherapy (60 Gy in 30 fractions) with concurrent chemotherapy. Clinical and dosimetric factors associated with PCE development were analyzed. RESULTS: The median follow-up was 37 months (range=8-111 months); the crude PCE incidence rate was 52.2%. Grade 2 and 3 incidence rate was 47.8% and 4.3%, respectively. The median time to PCE onset was 5.7 months after radiotherapy. In multivariate analysis, pericardial V30 ≥ 41.6%, age ≥ 66 years, body mass index (BMI) ≥ 19 and diabetes mellitus (DM) were significant predictors of developing PCE. CONCLUSION: The present study suggests that higher pericardial V30, advanced age, high BMI and DM are risk factors for developing PCE. Copyright
AIM: We investigated clinical and dosimetric factors influencing the risk of developing pericardial effusion (PCE) in patients with Stage I esophageal cancer undergoing definitive chemoradiotherapy. PATIENTS AND METHODS: Sixty-nine patients with Stage I esophageal cancer who underwent definitive chemoradiotherapy were retrospectively analyzed. Treatment comprised of three-dimensional conformal radiotherapy (60 Gy in 30 fractions) with concurrent chemotherapy. Clinical and dosimetric factors associated with PCE development were analyzed. RESULTS: The median follow-up was 37 months (range=8-111 months); the crude PCE incidence rate was 52.2%. Grade 2 and 3 incidence rate was 47.8% and 4.3%, respectively. The median time to PCE onset was 5.7 months after radiotherapy. In multivariate analysis, pericardial V30 ≥ 41.6%, age ≥ 66 years, body mass index (BMI) ≥ 19 and diabetes mellitus (DM) were significant predictors of developing PCE. CONCLUSION: The present study suggests that higher pericardial V30, advanced age, high BMI and DM are risk factors for developing PCE. Copyright
Authors: Szymon Darocha; Michał Wilk; Anna Walaszkowska-Czyż; Jarosław Kępski; Rafał Mańczak; Marcin Kurzyna; Adam Torbicki; Sebastian Szmit Journal: In Vivo Date: 2018 Mar-Apr Impact factor: 2.155